EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients

Paulina Jonéus, Per Johansson, Sophie Langenskiöld iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0290833 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Paulina Jonéus und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Dental and Pharmaceutical Benefits Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This paper presents results from one of the few comparative effectiveness evaluations of novel antiandrogen medications (NHT) against standard of care (SoC) for patients suffering from metastatic castrate-resistant prostate cancer (mCRPC).

Methods

The design and the analysis are published in a protocol before accessing outcome data. Two groups of patients are balanced on hundreds of important covariates measured before the prostate cancer diagnosis and up to the date of the prescription. While the design yields balance on the observed covariates, one cannot discard the possibility that unobserved confounders are not balanced. The unconfoundedness assumption is assessed by estimating placebo regressions on two health measures, not included in the design but added together with the outcome data after protocol publication.

Results

We find a substantial (64 percent) increase in mortality for patients prescribed with NHT rather than SoC. However, based on the results from one of the two placebo regressions, we cannot rule out that the difference in mortality may be due to confounding. Using a bounding strategy of the effect, we can, however, rule out that NHT reduces mortality compared to SoC. Under an empirical valid assumption that most mCRPC patients who die suffer from bone metastases, we have a strong indication of increased skeleton-related events in patients if prescribed NHT against SoC.

Conclusions

Generally, the SoC for this group of patients is docetaxel. Given the substantially higher costs of many of the NHT, the finding of no positive effects from NHT on both mortality and SRE is important. More comparative studies, including studies analysing quality of life outcomes, are thus needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantProstatic NeoplasmsMaleHumansStandard of CareQuality of LifeDocetaxelAndrogen Antagonists

Substanzen

DocetaxelAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Statistics, Uppsala University, Uppsala, Sweden.
  • Centre for Health-Economic Research, Uppsala University, Uppsala, Sweden.
  • YMSC, Tsinghua University, Beijing, China.
  • Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

ORCID-Profile: Sophie Langenskiöld

Förderung

  • The Dental and Pharmaceutical Benefits Agency

Zitieren

APA

Jonéus, P., Johansson, P., & Langenskiöld, S. (2024). Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0290833

Vancouver

Jonéus P, Johansson P, Langenskiöld S. Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0290833

BibTeX
@article{Jonus2024,
  author = {Jonéus, Paulina and Johansson, Per and Langenskiöld, Sophie},
  title = {Novel hormonal therapy versus standard of care—A registry-based comparative effectiveness evaluation for mCRPC-patients},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0290833}
}
Kostenlos starten →